Skip to content

SGLT2 Inhibitor

SGLT2 inhibitors are a class of medications that lower blood sugar by preventing the kidneys from reabsorbing glucose, leading to its excretion in urine. They are primarily used to manage type 2 diabetes but have shown potential benefits for cardiovascular health and weight management, making them relevant for longevity and health optimization.

Intelligence Profile

Safety Profile

SGLT2 inhibitors are a class of medications used in managing type 2 diabetes and have also shown benefits in heart failure and chronic kidney disease. Here's an overview of their safety profile based on the available evidence:

Known Side Effects

  1. Urinary Tract Infections (UTIs) and Genital Infections: SGLT2 inhibitors can increase the risk of UTIs and genital infections due to increased glucose in the urinary tract.
  2. Dehydration and Hypotension: They may lead to dehydration, resulting in low blood pressure, dizziness, or fainting, especially when combined with diuretics.
  3. Ketoacidosis: There is a risk of diabetic ketoacidosis, even in the absence of high blood glucose levels.
  4. Acute Kidney Injury: While generally renoprotective, initial decreased kidney function can occur, as noted in patients with prior angiotensin receptor-neprilysin inhibitor use.
  5. Potential Cognitive Impairment: Specific studies on dapagliflozin suggest potential cognitive effects, but evidence remains thin and requires further investigation.

Contraindications

  • Severe Renal Impairment: Not recommended for patients with severe kidney issues due to their mechanism which involves kidney function for glucose excretion.
  • Type 1 Diabetes: SGLT2 inhibitors are not approved for type 1 diabetes, where there's an increased risk of ketoacidosis.
  • Patients with Active Bladder Cancer: Use is cautioned due to uncertain safety data.

Drug Interactions

  • Care should be taken when used with diuretics and blood pressure medications to avoid extreme hypotension.
  • Caution when combined with insulin or sulfonylureas due to increased risk of hypoglycemia.

Populations to Avoid

  • Pregnant and Breastfeeding Women: Due to insufficient evidence regarding safety, these populations should avoid SGLT2 inhibitors.
  • Elderly Patients: As they have an increased risk of dehydration and renal side effects, careful monitoring is needed.

The evidence on SGLT2 inhibitors' safety is robust in certain areas like the risk of infections and dehydration, but still developing in others, such as cognitive effects. Always consult healthcare providers for personalized medical advice.

Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult a healthcare professional for medical concerns.

Free account required

Safety profile requires a free AXIFI account to access clinical data, safety profiles, and research papers.